相关临床试验
10
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
2
20.0%
招募中
8
80.0%
暂无批准数据
- Akums Drugs and Pharmaceuticals Limited received a 20-year patent for its "Dual Release Gastro-Resistant Composition" technology, granted on October 31, 2025, by the Indian Patent Office. - The patented formulation represents a next-generation proton pump inhibitor therapy designed for moderate to severe or treatment-resistant gastroesophageal reflux disease affecting 784 million people globally. - The innovative dual-release system delivers medication in two phases, with 50% released in the duodenum and 50% in the ileum, providing extended drug absorption and prolonged therapeutic action. - The once-daily formulation has received DCGI approval and utilizes tablet-in-tablet technology to address nocturnal acid breakthrough and incomplete symptom relief associated with conventional PPIs.
- Akums Drugs and Pharmaceuticals Limited has announced a joint venture with the Government of Zambia to establish a state-of-the-art pharmaceutical manufacturing facility, with Akums holding a 51% majority stake. - The facility, expected to be completed by 2028, will manufacture tablets, capsules, liquids, injectables, and beta-lactam products to serve Zambia's growing pharmaceutical market projected to exceed $300 million by 2030. - The Zambian government has committed to purchasing $25 million worth of medicines annually from Akums' Indian facilities in 2026 and 2027, while the new facility will also export to neighboring Southern African nations. - This partnership represents Akums' first international manufacturing venture and aims to reduce Zambia's 75% import dependency for essential medicines while supporting the country's move toward healthcare self-reliance.
